<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02743351</url>
  </required_header>
  <id_info>
    <org_study_id>PT-001</org_study_id>
    <nct_id>NCT02743351</nct_id>
  </id_info>
  <brief_title>Study of ProTmune for Allogeneic HCT in Adult Patients With Hematologic Malignancies</brief_title>
  <official_title>A Phase 1, Non-randomized, Open-Label/ Phase 2 Randomized, Blinded Study of ProTmuneâ„¢ (ex Vivo Programmed Mobilized Peripheral Blood Cells)Versus Non-Programmed Mobilized Peripheral Blood Cells for Allogeneic Hematopoietic Cell Transplantation in Adult Subjects With Hematologic Malignancies Patients With Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fate Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fate Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a Phase 1, Non-randomized, Open-label/Phase 2 Randomized, Blinded Study of&#xD;
      ProTmune (ex vivo programmed mobilized peripheral blood cells) Versus Non-programmed&#xD;
      mobilized peripheral blood cells for Allogeneic Hematopoietic Cell Transplantation (HCT) in&#xD;
      Adult Subjects Aged 18 years and older with Hematologic Malignancies. A maximum of 80 total&#xD;
      eligible subjects will be enrolled and treated in the trial at approximately 15-20 centers in&#xD;
      the US.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 2016</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Actual">December 4, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients that experience Grades II-IV acute Graft vs Host Disease (aGvHD)</measure>
    <time_frame>by Day 100</time_frame>
    <description>aGvHD assessments of skin, liver and gastrointestinal involvement will be required to calculate the incidence of Grades II through IV (CIBMTR) aGvHD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjects alive without relapse and moderate to severe chronic Graft vs Host Disease (cGvHD)</measure>
    <time_frame>By Day 365</time_frame>
    <description>Proportion of Subjects alive without relapse and without moderate or severe cGvHD at Visit Day +365</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hematologic Malignancies</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Acute Lymphoblastic Leukemia</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Chronic Myelogenous Leukemia</condition>
  <condition>Acute Graft-versus-host Disease</condition>
  <arm_group>
    <arm_group_label>ProTmune</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ProTmune</intervention_name>
    <description>Ex-vivo, programmed mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>ProTmune</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Control Arm</intervention_name>
    <description>Untreated mobilized peripheral blood (mPB) cells</description>
    <arm_group_label>Control Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Male and female patients aged 18 years and older, inclusive;&#xD;
&#xD;
          2. Patients must have a hematologic malignancy for which allogeneic hematopoietic&#xD;
             peripheral blood cell transplantation is deemed clinically appropriate.&#xD;
&#xD;
             Eligible diseases and stages include the following:&#xD;
&#xD;
               1. Acute myeloid leukemia&#xD;
&#xD;
               2. Acute lymphoblastic leukemia, including T lymphoblastic lymphoma with a history&#xD;
                  of marrow involvement&#xD;
&#xD;
               3. Myelodysplatic Syndrome&#xD;
&#xD;
               4. Chronic Myelogenous leukemia&#xD;
&#xD;
          3. Availability of a suitable 8/8 HLA-A, -B, -C, and -DRB1-matched unrelated mPB donor;&#xD;
&#xD;
          4. mBP donor collection that meets protocol specifications;&#xD;
&#xD;
          5. Adequate performance status, defined as Karnofsky score greater than 70%;&#xD;
&#xD;
          6. For female patients of childbearing potential, all of the following criteria must be&#xD;
             met:&#xD;
&#xD;
               -  They are not pregnant (i.e., female patients must have a negative serum pregnancy&#xD;
                  test at screening);&#xD;
&#xD;
               -  They are not breastfeeding;&#xD;
&#xD;
               -  They do not plan to become pregnant during the study; and&#xD;
&#xD;
               -  They are using an effective method of contraception from screening to the end of&#xD;
                  the study, unless their sexual partner is surgically sterile&#xD;
&#xD;
          7. For male patients, agreement to use condoms with spermicide during sexual intercourse&#xD;
             from screening to the end of study; and&#xD;
&#xD;
          8. Willingness and ability to sign an IRB/IEC approved ICF before performance of any&#xD;
             study specific procedures or tests and to comply with protocol visits, and study&#xD;
             procedures.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Phase 1 only: known bone marrow fibrosis; Phase 2 only: Bone marrow fibrosis grade 3&#xD;
             (severe) or greater;&#xD;
&#xD;
          2. Positive serology for human immunodeficiency virus (HIV) or human T-cell lymphotropic&#xD;
             virus (HTLV) at any time prior to enrollment;&#xD;
&#xD;
          3. Currently uncontrolled bacterial, viral, or fungal infection (progression of clinical&#xD;
             symptoms despite therapy);&#xD;
&#xD;
          4. Prior autologous or allogeneic HCT;&#xD;
&#xD;
          5. Active malignancy, other than the one for which the allogeneic mPB transplant is being&#xD;
             performed, within 12 months of enrollment, excluding superficial basal cell and&#xD;
             carcinoma in situ cervical cancer;&#xD;
&#xD;
          6. Pulmonary disease, renal dysfunction, hepatic disease, cardiac disease, neurologic&#xD;
             disease;&#xD;
&#xD;
          7. Participation in another clinical trial involving an investigational product within 30&#xD;
             days prior to screening; or&#xD;
&#xD;
          8. Any condition or therapy, which, in the opinion of the Investigator, might pose a risk&#xD;
             to the patient or make participation in the study not in the best interest of the&#xD;
             patient.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sarah Cooley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Fate Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, San Diego (UCSD) Moores Cancer Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana Blood and Marrow Transplant</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Ann Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Transplant Institute</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute (University of Utah)</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 9, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2016</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cell Transplants</keyword>
  <keyword>Hematopoietic Cell Transplant</keyword>
  <keyword>HSCT</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Hematologic Malignancy</keyword>
  <keyword>Acute Myeloid Leukemia</keyword>
  <keyword>Acute Lymphoblastic Leukemia</keyword>
  <keyword>ALL</keyword>
  <keyword>AML</keyword>
  <keyword>Myelodysplastic Syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Allogeneic</keyword>
  <keyword>CML</keyword>
  <keyword>Stem Cell Transplant</keyword>
  <keyword>Transplant</keyword>
  <keyword>aGvHD</keyword>
  <keyword>Acute graft-versus-host Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

